Who
Robert S. Epstein
Director
Company insider
Files Form 4 as: Director, Fate Therapeutics; Director, Veracyte; Director, Illumina; Director, Aveo Pharmaceuticals; Pres, United BioSource Corp., Medco Health Solutions.
In numbers
- Trades disclosed
- 235
- Buys
- 0
- Sells
- 46
- Bought
- $0
- Sold
- $32.1M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 27 Feb 2006
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —5,272 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —5,272 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $440K10,000 at $44.01 | filing |
| 20 May 2026filed 22 May 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $440K10,000 at $44.01 | filing |
| 5 May 2026filed 6 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K25,000 at $1.69 | filing |
| 5 May 2026filed 6 May 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K25,000 at $1.69 | filing |
| 1 Oct 2025filed 3 Oct 2025 | VCYT Veracyteoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code M | $79K10,000 at $7.94 | filing |
| 1 Oct 2025filed 3 Oct 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $753K21,473 at $35.08 | filing |
| 18 Jun 2025filed 23 Jun 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —9,321 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 21 May 2025filed 23 May 2025 | ILMN IlluminaLife-science tools | SEC FORM 4 Code A | —3,780 at $0.00 | filing |
| 6 Jan 2025filed 8 Jan 2025 | VCYT Veracyteoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 6 Jan 2025filed 8 Jan 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code M | $161K20,000 at $8.04 | filing |
| 12 Nov 2024filed 14 Nov 2024 | VCYT Veracyteoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 12 Nov 2024filed 14 Nov 2024 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code M | $121K15,000 at $8.04 | filing |
News
Mammogen Appoints Diagnostics Industry Leader, Dr. Robert S. Epstein, to Board of Directorsmanilatimes.net · 13 Oct 2026
1 headline in the last 90 days name Robert S. Epstein; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.